NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Clinical trial NCT06737250 · RECRUITING

Trial details

NCT number: NCT06737250
Sponsor: NOBO Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary CNS Lymphoma (PCNSL)

Start date: 2024-11-25
Primary completion: 2026-06-30
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.